ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2518

Impact of psychiatric comorbidity on disease outcomes in ANCA-associated vasculitis: A multi-center retrospective cohort study

Saloni Patel1, Brendan Denvir2, Maria Kaltchenko1, Aaron Bao3, Varsha Simha1, Michael Cammarata4 and Jun Kang5, 1Johns Hopkins University School of Medicine, Baltimore, 2Johns Hopkins, Baltimore, MD, 3Johns Hopkins School of Medicine, Baltimore, MD, 4Johns Hopkins, Phoenix, MD, 5Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: ACR Convergence 2025

Keywords: ANCA associated vasculitis, Disparities, psychological status, psychosocial factors, risk assessment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2504–2523) Vasculitis – ANCA-Associated Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic small vessel vasculitis associated with significant morbidity and complex care needs across a broad demographic spectrum. While prior studies have demonstrated an increased prevalence of mental health disorders among patients with AAV, the impact of pre-existing psychiatric conditions on disease outcomes remains insufficiently characterized. Given the potential interplay between psychiatric comorbidities and systemic inflammation, further investigation is warranted. This study aims to evaluate the influence of pre-existing psychiatric disorders on clinical outcomes and treatment patterns in adult patients diagnosed with AAV.

Methods: We conducted a retrospective cohort study using the TriNetX network, comparing adult AAV patients with and without pre-existing psychiatric diagnoses (schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, or persistent mood disorder). Propensity score matching was performed for age, sex, race, and smoking status. Five-year incident risk of chronic renal disease, pulmonary disease, infections, venous thromboembolism, glucocorticoid use, and glucocorticoid-associated toxicities were compared using relative risk (RR) with 95% confidence intervals (CI). The ICD-10 and RxNorm codes corresponding to these outcomes, as defined within the TriNetX database, are presented in Table 1.

Results: A total of 1,121 AAV patients with preexisting psychiatric disorders and 17,465 without were included, with 1,116 patients in each cohort after matching (Table 2). Before matching, psychiatric comorbidity was associated with higher risks of acute kidney failure (RR 1.31, 95% CI 1.04–1.64), respiratory failure (1.59, 1.29–1.95), venous thromboembolism (1.37, 1.02–1.86), and infections. After matching, psychiatric comorbidity remained associated with increased risks of pneumonia (1.45, 1.09–1.94), skin infections (1.93, 1.40–2.67), sepsis (1.41, 1.01–1.96), and viral infections (1.55, 1.13–2.13). In unmatched analyses, patients with psychiatric disorders were more likely to be prescribed glucocorticoids (1.13, 1.09–1.18) and less likely to receive glucocorticoid-sparing immunosuppressants (0.81, 0.71–0.92); the latter association persisted after matching (Figure 1).

Conclusion: In AAV, pre-existing psychiatric disorders are associated with increased infectious complications and decreased prescription of glucocorticoid-sparing therapies. Future research should investigate potential co-inflammatory interactions between psychiatric disorders and AAV, and socioenvironmental factors influencing medication adherence and access to care.

Supporting image 1

Supporting image 2Abbreviations: AAV=ANCA-associated vasculitis, GPA=Granulomatosis with polyangiitis, MPA=Microscopic polyangiitis, EGPA=Eosinophilic granulomatosis with polyangiitis.

*Covariates included in the propensity-score matched analysis

Supporting image 3Relative risk of 5-year incident outcomes in adult ANCA-associated vasculitis (AAV) patients with a pre-existing psychiatric comorbidity. The reference group for both plots is the cohort of adult patients with AAV and no documented psychiatric disorder (schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, or persistent mood disorder) at any time point. Plot A shows the unadjusted analyses and plot B displays the adjusted analyses after propensity-score matching for age at AAV diagnosis, sex, race, and nicotine dependence in a 1:1 ratio between the cohort of interest and the reference cohort. The dashed gray vertical line in both plots represents no difference in relative risk between the cohorts. Plots highlighted in red indicate a statistically significant difference between cohorts.


Disclosures: S. Patel: None; B. Denvir: None; M. Kaltchenko: None; A. Bao: None; V. Simha: None; M. Cammarata: None; J. Kang: AstraZeneca, 12,, 5.

To cite this abstract in AMA style:

Patel S, Denvir B, Kaltchenko M, Bao A, Simha V, Cammarata M, Kang J. Impact of psychiatric comorbidity on disease outcomes in ANCA-associated vasculitis: A multi-center retrospective cohort study [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/impact-of-psychiatric-comorbidity-on-disease-outcomes-in-anca-associated-vasculitis-a-multi-center-retrospective-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-psychiatric-comorbidity-on-disease-outcomes-in-anca-associated-vasculitis-a-multi-center-retrospective-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology